Crinetics Pharmaceuticals (CRNX) Earnings Date & Reports

Key Takeaways

• Crinetics Pharmaceuticals (CRNX) is scheduled to report second-quarter 2026 financial results on Monday, August 4, after the market closes.
• Wall Street consensus expects a net loss of approximately $1.19 to $1.27 per share, with revenue estimates clustering around $14.8 million to $15.1 million.
• All eyes will be on PALSONIFY (paltusotine) commercial momentum, including new patient enrollment forms, prescriber growth, and reimbursement trends.
• This earnings report arrives just weeks after Vertex Pharmaceuticals announced a $10 billion all-cash acquisition of Crinetics at $85 per share, reshaping the investment thesis.
• With the stock now trading near the deal price, earnings-related price swings may be muted, but operating performance remains relevant for deal-closing confidence.

Earnings Context and Why It Matters

Crinetics Pharmaceuticals enters its second-quarter 2026 earnings report at a pivotal moment. The company received U.S. Food and Drug Administration (FDA) approval for PALSONIFY in September 2025, making it the first once-daily oral treatment for adults with acromegaly, a rare endocrine disorder. The Q2 report represents the third full quarter of PALSONIFY's commercial launch and will offer the most meaningful read yet on the drug's real-world uptake trajectory. Adding to the significance, Vertex Pharmaceuticals announced on July 6 that it will acquire Crinetics for approximately $10 billion, or $85 per share in cash. The deal is expected to close in the third quarter of 2026. While the acquisition creates a natural ceiling on CRNX's stock price, the earnings call may provide important updates on commercial execution and pipeline milestones ahead of the transaction's close.

Earnings Expectations

Analysts tracking Crinetics project a second-quarter net loss in the range of $1.19 to $1.29 per share, with the consensus estimate settling near $1.19, according to MarketWatch and Finviz data. For context, CRNX reported a loss of $1.23 per share in Q2 2025, though year-ago comparisons carry limited significance given the company's transition from a pre-revenue clinical-stage biotech to a commercial-stage enterprise.

On the top line, consensus revenue estimates span approximately $14.8 million to $15.1 million, representing more than 1,300% year-over-year growth from the roughly $1.0 million reported in Q2 2025. The overwhelming majority of expected revenue will come from PALSONIFY net product sales. In Q1 2026, Crinetics generated $10.3 million in net product revenue from PALSONIFY, with an additional $0.4 million from licensing agreements. Sequential revenue growth will be closely scrutinized as a gauge of commercial launch momentum.

Key operating metrics investors should watch include the number of new patient enrollment forms (232 were added in Q1), growth in unique prescribers (263 as of March 31), and the percentage of patients on reimbursed therapy (approximately 70% at the end of Q1). Management previously indicated it expects to exceed a 75% payer coverage goal by the end of Q3 2026. The company has also maintained its 2026 guidance for GAAP (Generally Accepted Accounting Principles) operating expenses of $600 million to $650 million and non-GAAP operating expenses of $480 million to $520 million. Research and development (R&D) expenses, which reached $100.1 million in Q1, will be another focal point as the company advances multiple late-stage clinical programs.

AI Screener

For investors seeking to identify stocks with similar catalysts, the AI Screener from Tickeron offers a powerful AI-driven solution for scanning thousands of equities and ETFs (exchange-traded funds) based on technical patterns, fundamental metrics, volatility profiles, and proprietary AI signals. The platform allows users to apply customizable filters — including industry, market capitalization, technical indicators, price patterns, and performance metrics — to surface trade ideas, breakout candidates, and trending stocks far more efficiently than through manual screening. Whether you are tracking biotech earnings season or hunting for the next sector rotation, the AI Screener can help streamline your research process.

Market Reaction and Investor Sentiment

Crinetics shares have undergone a dramatic transformation in recent weeks. Before Vertex's acquisition announcement on July 6, the stock traded around $42 per share and had spent much of 2026 consolidating. The $85-per-share all-cash offer — representing a 102% premium — sent CRNX surging nearly 99% in a single session, and shares now trade in the $83 to $84 range, just below the deal price.

Following the announcement, multiple analyst firms — including Oppenheimer, Cantor Fitzgerald, Stifel, JonesTrading, Piper Sandler, and TD Cowen — downgraded CRNX to Hold-equivalent ratings, reflecting the view that the stock will now trade based on the acquisition rather than standalone fundamentals. The current consensus analyst rating stands at Hold, with an average price target of approximately $82.50. With the narrow spread between the current stock price and the $85 acquisition price, earnings-driven volatility is likely to be limited unless the quarterly update surfaces unexpected commercial weakness or deal-related complications.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, several themes warrant investor attention as Crinetics approaches its expected integration into Vertex Pharmaceuticals.

The PALSONIFY commercial rollout remains the most immediate value driver. Management commentary around prescriber breadth, the trajectory of enrollment form conversions to paid therapy, and progress toward the 75% reimbursement coverage target will shape confidence in the drug's ultimate market opportunity. Cantor Fitzgerald previously noted it expected quarterly revenue growth to accelerate to more than $10 million per quarter starting in Q2 2026. Whether that pace materializes will be a key test.

On the pipeline front, Crinetics has four pivotal clinical trials actively recruiting or running. Atumelnant, the company's late-stage candidate for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome, continues to advance through Phase 3 studies. Additionally, PALSONIFY is being evaluated in a Phase 3 trial for carcinoid syndrome associated with neuroendocrine tumors, while CRN09682, a nonpeptide drug conjugate (a next-generation targeted therapy combining a small-molecule targeting agent with a drug payload), remains in dose escalation for neuroendocrine tumors.

With the Vertex acquisition expected to close this quarter, the earnings call may also offer subtle cues about the integration timeline, any regulatory or antitrust review updates, and whether Crinetics' $1.3 billion cash position remains fully intact. For current shareholders, the primary question is whether any obstacle — regulatory, commercial, or otherwise — could threaten the deal's completion. For the broader market, Crinetics' commercial data serves as a real-world case study in launching a rare-disease oral therapy in a market historically dominated by injectable treatments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations